Daily News Podcast

Finally, new migraine drugs

Publish date: August 1, 2018

 

Successful phase 3 data for new headache medications (rimegepant, ubrogepant, lasmiditan) are finally raining in after a lengthy drought. Also today, interferon status and family history predict autoimmune connective tissue disease, steroid injection before rotator cuff repair predicts revision, and the CMS resumes risk adjustment payments for 2017. Listen to the MDedge Daily News for today’s top news.

Recommended Reading

Telemedicine payment expansion?
MDedge Endocrinology
Bundle pay plan didn’t save money
MDedge Endocrinology
Brain damage, slight benefit seen in epinephrine cardiac arrest
MDedge Endocrinology
Is fibromyalgia one disorder – or two?
MDedge Endocrinology
Is fish oil’s heart benefit a fish tale?
MDedge Endocrinology
Blood pressure meds cut cognitive impairment risk
MDedge Endocrinology
Antibody cleared amyloid plaques, slowed cognitive decline
MDedge Endocrinology
CTCs linked to late recurrence in HER2–, HR+ breast cancer
MDedge Endocrinology
Free skin cancer screening highlights need
MDedge Endocrinology
Valsartan cancer risk is low
MDedge Endocrinology